BCMA and CD3 bispecific T cell engaging antibody constructs

US11352433B2 · kind B2 · utility

Assignees

• AMGEN RESEARCH (MUNICH) GMBH · DE
• AMGEN INC. · US

Inventors

• Tobias Raum · Munich, DE
• Markus Münz · Munich, DE
• Johannes Brozy · Munich, DE
• Peter Kufer · Munich, DE
• Patrick Hoffmann · Munich, DE
• Matthias Friedrich · Munich, DE
• Benno Rattel · Munich, DE
• Pamela Bogner · Munich, DE
• Andreas Wolf · Gauting, DE
• Cornelius Pompe · Munich, DE

Key dates

• Filing date: Apr 2, 2019
• Grant date: Jun 7, 2022
• Expiry date: May 14, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.